Liposomes as topical drug delivery systems: State of the arts

Rahman, Mahfoozur; Alam, Kainat; Beg, Sarwar; Anwar, Firoz; Kumar, Vikas

doi:10.1016/b978-0-12-816506-5.00004-8

Cited by 9 publications

(2 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once injected into the blood circulation, liposomes passively extravasate and accumulate at the sites of inflammation 20 . This improved drug distribution typically leads to an increase in drug efficacy and a reduction of side effects and toxicity 21–23 . We produced PEG liposomes labeled with 1% of lipophilic tracer DID with fluorescence excitation and emission spectra that allow optical imaging in the near infrared window.…”

Section: Resultsmentioning

confidence: 99%

“…20 This improved drug distribution typically leads to an increase in drug efficacy and a reduction of side effects and toxicity. [21][22][23] We produced PEG liposomes labeled with 1% of lipophilic tracer DID with fluorescence excitation and emission spectra that allow optical imaging in the near infrared window. CIA or control DBA/1OlaHsd mice were injected at day 27 with empty DID1% PEG liposomes.…”

Section: Pegmentioning

confidence: 99%

See 1 more Smart Citation

Liposomal AntagomiR‐155‐5p Restores Anti‐Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid Arthritis

Paoletti,

Ly,

Cailleau

et al. 2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

IntroductionWe previously reported an increased expression of miR‐155 in rheumatoid arthritis (RA) patients blood monocytes that could be responsible for impaired monocyte polarization to anti‐inflammatory M2‐like macrophages. In this study, we employed two pre‐clinical models of RA: the Collagen‐Induce‐Arthritis (CIA) and the K/BxN Serum‐Transfer‐Arthritis (STA), to examine the therapeutic potential of antagomiR‐155‐5p entrapped within PEGylated (PEG)‐liposomes in resolution of arthritis and re‐polarization of monocytes towards anti‐inflammatory M2 phenotype.MethodsAntagomiR‐155‐5p or antagomiR‐control were encapsulated in PEG‐liposomes of 100 nm in size and ‐10mV in zeta potential with high antagomiR loading efficiency (above 80%). Mice were injected intravenously with 1,5nmol/100μL PEG‐liposomes containing antagomiR‐155‐5p or control after induction of arthritis.ResultsWe demonstrated the biodistribution of fluorescently tagged‐PEG‐liposomes to inflamed joints 1 hour after injection of fluorescently tagged‐PEG‐liposomes and as well as their subsequent liver's accumulation after 48 hours, indicative of hepatic clearance, in arthritic mice. Injection of PEG‐liposomes containing antagomiR‐155‐5p decreased arthritis score and paw swelling as compared to PEG‐liposomes containing antagomiR‐control or systemic delivery of free antagomiR‐155‐5p. Moreover, treatment with PEG‐liposomes containing antagomiR‐155‐5p lead to the restoration of bone marrow monocytes defect in anti‐inflammatory macrophage differentiation without any significant functional change in other immune cells including splenic B and T cells.ConclusionThe injection of antagomiR‐155‐5p encapsulated in PEG‐liposomes allows delivering small RNA to monocytes/macrophages, reduced joint inflammation in murine models of RA, providing a promising strategy in human disease.image

show abstract

Section: Resultsmentioning

confidence: 99%